| 1 |
Tu Z, Wang X, Cai H, Sheng Y, Wu L, Huang K, Zhu X. The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker. Aging (Albany NY) 2023;15. [PMID: 36961395 DOI: 10.18632/aging.204601] [Reference Citation Analysis]
|
| 2 |
Zhang S, Ni Q. Prognostic role of the pretreatment systemic immune-inflammation index in patients with glioma: A meta-analysis. Front Neurol 2023;14. [DOI: 10.3389/fneur.2023.1094364] [Reference Citation Analysis]
|
| 3 |
Li H, Sun X, Zhao Y, Zhang C, Jiang K, Ren J, Xing L, He M. Pan-Cancer Analysis of TASL: A Novel Immune Infiltration-Related Biomarker for Tumor Prognosis and Immunotherapy Response Prediction.. [DOI: 10.21203/rs.3.rs-2576721/v1] [Reference Citation Analysis]
|
| 4 |
He Y, Zhang X, Zhang S, Zhang Y, Xie B, Huang M, Zhang J, Shen L, Long W, Liu Q. Prognostic RNA-editing signature predicts immune functions and therapy responses in gliomas. Front Genet 2023;14:1120354. [PMID: 36845382 DOI: 10.3389/fgene.2023.1120354] [Reference Citation Analysis]
|
| 5 |
Chen X, Wu W, Wang Y, Zhang B, Zhou H, Xiang J, Li X, Yu H, Bai X, Xie W, Lian M, Wang M, Wang J. Development of prognostic indicator based on NAD+ metabolism related genes in glioma. Front Surg 2023;10:1071259. [PMID: 36778644 DOI: 10.3389/fsurg.2023.1071259] [Reference Citation Analysis]
|
| 6 |
Li Y, Zhu Y, Chen L, Xia S, Adegboro AA, Wanggou S, Li X. Transcription factor ZBTB42 is a novel prognostic factor associated with immune cell infiltration in glioma. Front Pharmacol 2023;14:1102277. [PMID: 36762114 DOI: 10.3389/fphar.2023.1102277] [Reference Citation Analysis]
|
| 7 |
Wang Y, Li M, Wang G, Wu H. Role of B7 family members in glioma: Promising new targets for tumor immunotherapy. Front Oncol 2022;12:1091383. [PMID: 36741734 DOI: 10.3389/fonc.2022.1091383] [Reference Citation Analysis]
|
| 8 |
Zhou Y, Xiao X, Peng C, Song D, Ouyang F, Wang L. Progesterone induces glioblastoma cell apoptosis by coactivating extrinsic and intrinsic apoptotic pathways. Mol Cell Toxicol 2023. [DOI: 10.1007/s13273-022-00327-w] [Reference Citation Analysis]
|
| 9 |
Wang J, Xiang C, Cai Y, Mei Z, Lu Q, Liu B, Zou L. Clinicopathological and prognostic significance of COX-2 in glioma patients: a meta-analysis. Arq Neuropsiquiatr 2022;80:1254-61. [PMID: 36580964 DOI: 10.1055/s-0042-1758864] [Reference Citation Analysis]
|
| 10 |
Zhou J, Li L, Jia M, Liao Q, Peng G, Luo G, Zhou Y. Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions. Cancer Medicine 2022. [DOI: 10.1002/cam4.5511] [Reference Citation Analysis]
|
| 11 |
He Y, Zhang S, Zhang X, Zhang Y, Xie B, Zhang J, Long W, Liu Q. A prognostic cuproptosis gene signature predicts immune function and chemotherapy response in gliomas.. [DOI: 10.21203/rs.3.rs-2155356/v1] [Reference Citation Analysis]
|
| 12 |
Xu C, Liu Y, Zhang Y, Gao L. The role of a cuproptosis-related prognostic signature in colon cancer tumor microenvironment and immune responses. Front Genet 2022;13:928105. [DOI: 10.3389/fgene.2022.928105] [Reference Citation Analysis]
|
| 13 |
Fan X, Nie X, Huang J, Zhang L, Wang X, Lu M, Cheng Q. A Composite Bioinformatic Analysis to Explore Endoplasmic Reticulum Stress-Related Prognostic Marker and Potential Pathogenic Mechanisms in Glioma by Integrating Multiomics Data. Journal of Oncology 2022;2022:1-28. [DOI: 10.1155/2022/9886044] [Reference Citation Analysis]
|
| 14 |
Fan X, Nie X, Huang J, Zhang L, Wang X, Lu M. A Composite Bioinformatic Analysis to Explore Endoplasmic Reticulum Stress-Related Prognostic Marker and Potential Pathogenic Mechanisms in Glioma by Integrating Multiomics Data. Journal of Oncology 2022;2022:1-28. [DOI: 10.1155/2022/9886044] [Reference Citation Analysis]
|
| 15 |
Fan X, Nie X, Huang J, Zhang L, Wang X, Lu M. A Composite Bioinformatic Analysis to Explore Endoplasmic Reticulum Stress-Related Prognostic Marker and Potential Pathogenic Mechanisms in Glioma by Integrating Multiomics Data. Journal of Oncology 2022;2022:1-28. [DOI: 10.1155/2022/9886044] [Reference Citation Analysis]
|
| 16 |
Lin W, Wang Q, Chen Y, Wang N, Ni Q, Qi C, Wang Q, Zhu Y. Identification of a 6-RBP gene signature for a comprehensive analysis of glioma and ischemic stroke: Cognitive impairment and aging-related hypoxic stress. Front Aging Neurosci 2022;14:951197. [DOI: 10.3389/fnagi.2022.951197] [Reference Citation Analysis]
|
| 17 |
Li S, Li J, Fan Y, Huang T, Zhou Y, Fan H, Zhang Q, Qiu R. The mechanism of formononetin/calycosin compound optimizing the effects of temozolomide on C6 malignant glioma based on metabolomics and network pharmacology. Biomed Pharmacother 2022;153:113418. [PMID: 36076540 DOI: 10.1016/j.biopha.2022.113418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 18 |
Zong W, Liu C, Zhang Y, Zhang S, Qu W, Luo X, Pan J. Identification of a Signature for Predicting Prognosis and Immunotherapy Response in Patients with Glioma. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/8615949] [Reference Citation Analysis]
|
| 19 |
Wang X, Han M, Chen S, Sun Y, Tan R, Huang B. The copper-associated protein STEAP2 correlated with glioma prognosis and immune infiltration. Front Cell Neurosci 2022;16:944682. [DOI: 10.3389/fncel.2022.944682] [Reference Citation Analysis]
|
| 20 |
Yan X, Wang N, Dong J, Wang F, Zhang J, Hu X, Zhao H, Gao X, Liu Z, Li Y, Hu S. A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma. Front Mol Biosci 2022;9:966843. [DOI: 10.3389/fmolb.2022.966843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Huang K, Rao C, Li Q, Lu J, Zhu Z, Wang C, Tu M, Shen C, Zheng S, Chen X, Lv F. Construction and validation of a glioblastoma prognostic model based on immune-related genes. Front Neurol 2022;13:902402. [DOI: 10.3389/fneur.2022.902402] [Reference Citation Analysis]
|
| 22 |
Zhu H, Hu X, Feng S, Gu L, Jian Z, Zou N, Xiong X. Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients. Front Immunol 2022;13:946692. [DOI: 10.3389/fimmu.2022.946692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Cao K, Jiang X, Wang B, Ni Z, Chen Y. SAA1 Expression as a Potential Prognostic Marker of the Tumor Microenvironment in Glioblastoma. Front Neurol 2022;13:905561. [PMID: 35756918 DOI: 10.3389/fneur.2022.905561] [Reference Citation Analysis]
|
| 24 |
Chen M, Huang B, Zhu L, Wang Q, Pang Y, Cheng M, Lian H, Liu M, Zhao K, Xu S, Zhang J, Zhong C. DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma. Front Immunol 2022;13:875648. [PMID: 35720326 DOI: 10.3389/fimmu.2022.875648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Wang Z, Huang R, Wang H, Peng Y, Fan Y, Feng Z, Zeng Z, Ji Y, Wang Y, Lu J. Prognostic and Immunological Role of PPP1R14A as a Pan-Cancer Analysis Candidate. Front Genet 2022;13:842975. [PMID: 35656324 DOI: 10.3389/fgene.2022.842975] [Reference Citation Analysis]
|
| 26 |
Liang M, Li J, Han L. Receptor-mediated cascade targeting strategies for the application to medical diagnoses and therapeutics of glioma. J Nanopart Res 2022;24. [DOI: 10.1007/s11051-022-05482-8] [Reference Citation Analysis]
|
| 27 |
Zhu Y, Feng S, Song Z, Wang Z, Chen G. Identification of Immunological Characteristics and Immune Subtypes Based on Single-Sample Gene Set Enrichment Analysis Algorithm in Lower-Grade Glioma. Front Genet 2022;13:894865. [DOI: 10.3389/fgene.2022.894865] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 28 |
Afonso M, Brito MA. Therapeutic Options in Neuro-Oncology. Int J Mol Sci 2022;23:5351. [PMID: 35628161 DOI: 10.3390/ijms23105351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 29 |
Li S, Zhang N, Liu S, Zhang H, Liu J, Qi Y, Zhang Q, Li X. ITGA5 Is a Novel Oncogenic Biomarker and Correlates With Tumor Immune Microenvironment in Gliomas. Front Oncol 2022;12:844144. [DOI: 10.3389/fonc.2022.844144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 30 |
Andersen JK, Miletic H, Hossain JA. Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities. Cancers 2022;14:1319. [DOI: 10.3390/cancers14051319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 31 |
Zhang J, Wang N, Wu J, Gao X, Zhao H, Liu Z, Yan X, Dong J, Wang F, Ba Y, Ma S, Jin J, Du J, Ji H, Hu S. 5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas. Front Immunol 2022;13:844778. [DOI: 10.3389/fimmu.2022.844778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 32 |
Yan T, Tian D, Chen J, Tan Y, Cheng Y, Ye L, Deng G, Liu B, Yuan F, Zhang S, Cai L, Chen Q. FCGBP Is a Prognostic Biomarker and Associated With Immune Infiltration in Glioma. Front Oncol 2021;11:769033. [PMID: 35047393 DOI: 10.3389/fonc.2021.769033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 33 |
Ji H, Zhao H, Jin J, Liu Z, Gao X, Wang F, Dong J, Yan X, Zhang J, Wang N, Du J, Hu S. Novel Immune-Related Gene-Based Signature Characterizing an Inflamed Microenvironment Predicts Prognosis and Radiotherapy Efficacy in Glioblastoma. Front Genet 2022;12:736187. [DOI: 10.3389/fgene.2021.736187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Fang DD, Huang W, Cheng G, Liu XN, Liu SM, Hou BS, Mao J, Zhou H. Clinicopathological and Prognostic Significance of ABCC3 in Human Glioma. J Oncol 2021;2021:1827992. [PMID: 34976054 DOI: 10.1155/2021/1827992] [Reference Citation Analysis]
|
| 35 |
Sabahi M, Hanaei S, Rezaei N. Interdisciplinary Approach in Neurological Cancers. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_68] [Reference Citation Analysis]
|
| 36 |
Malliou A, Kyritsis AP, Alexiou GA. Immunotherapeutic Strategies for Glioma Treatment. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_71] [Reference Citation Analysis]
|
| 37 |
Francipane MG, Douradinha B, Chinnici CM, Russelli G, Conaldi PG, Iannolo G. Zika Virus: A New Therapeutic Candidate for Glioblastoma Treatment. Int J Mol Sci 2021;22:10996. [PMID: 34681654 DOI: 10.3390/ijms222010996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 38 |
Li H, Wang G, Wang W, Pan J, Zhou H, Han X, Su L, Ma Z, Hou L, Xue X. A Focal Adhesion-Related Gene Signature Predicts Prognosis in Glioma and Correlates With Radiation Response and Immune Microenvironment. Front Oncol 2021;11:698278. [PMID: 34631528 DOI: 10.3389/fonc.2021.698278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 39 |
Shadbad MA, Asadzadeh Z, Hosseinkhani N, Derakhshani A, Alizadeh N, Brunetti O, Silvestris N, Baradaran B. A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology. Front Immunol 2021;12:734956. [PMID: 34603316 DOI: 10.3389/fimmu.2021.734956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 40 |
Ji H, Ba Y, Ma S, Hou K, Mi S, Gao X, Jin J, Gong Q, Liu T, Wang F, Liu Z, Li S, Du J, Hu S. Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy. Front Immunol 2021;12:729359. [PMID: 34566988 DOI: 10.3389/fimmu.2021.729359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 41 |
Lin Z, Wen M, Yu E, Lin X, Wang H, Chen J, Yao C, Zhang H, Ru J, Wang K, Zhang Y, Huang L, Zhuge Q, Yang S. ANXA1 as a Prognostic and Immune Microenvironmental Marker for Gliomas Based on Transcriptomic Analysis and Experimental Validation. Front Cell Dev Biol 2021;9:659080. [PMID: 34422796 DOI: 10.3389/fcell.2021.659080] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 42 |
Zhang J, Fu M, Zhang M, Zhang J, Du Z, Zhang H, Hua W, Mao Y. DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker. Front Oncol 2021;11:665360. [DOI: 10.3389/fonc.2021.665360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 43 |
Wang G, Zhou H, Tian L, Yan T, Han X, Chen P, Li H, Wang W, Xiao Z, Hou L, Xue X. A Prognostic DNA Damage Repair Genes Signature and Its Impact on Immune Cell Infiltration in Glioma. Front Oncol 2021;11:682932. [PMID: 34123852 DOI: 10.3389/fonc.2021.682932] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 44 |
Cai X, Yuan F, Zhu J, Yang J, Tang C, Cong Z, Ma C. Glioma-Associated Stromal Cells Stimulate Glioma Malignancy by Regulating the Tumor Immune Microenvironment. Front Oncol 2021;11:672928. [PMID: 33996602 DOI: 10.3389/fonc.2021.672928] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 45 |
Tian R, Li Y, Liu Q, Shu M. Identification and Validation of an Immune-Associated RNA-Binding Proteins Signature to Predict Clinical Outcomes and Therapeutic Responses in Glioma Patients. Cancers (Basel) 2021;13:1730. [PMID: 33917399 DOI: 10.3390/cancers13071730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 46 |
Luo H, Tao C, Wang P, Li J, Huang K, Zhu X. Development of a prognostic index based on immunogenomic landscape analysis in glioma. Immun Inflamm Dis 2021;9:467-79. [PMID: 33503296 DOI: 10.1002/iid3.407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
